Show Notes
In this episode of The Good GP, host Dr Sean Stevens is joined by Dr Terri-Lynne South live from the GP25 Conference, to deliver an overview of obesity management, with a specific focus on the use of GLP-1 and GIP dual incretin therapies in general practice. Dr Terri-Lynne South outlines the current Therapeutic Goods Administration (TGA)-approved indications for these treatments in Australia. These include use in patients with type 2 diabetes, overweight with complications, chronic kidney disease and type 2 diabetes, obesity with obstructive sleep apnoea, and secondary prevention of cardiovascular disease. Noting that this field is rapidly evolving, with recent changes in indications and ongoing international developments.
Addressing the importance of setting realistic patient expectations regarding weight loss outcomes and the duration of treatment, emphasising that clinical obesity is a chronic, complex condition requiring long-term management. Evidence shows that weight loss achieved with GLP-1 therapies can be maintained over four years if the patient remains adherent, while early discontinuation often leads to significant weight regain.
Practical strategies for managing common side effects, mainly gastrointestinal symptoms like nausea and constipation, are described in detail. Dr Terri-Lynne South provides useful tips for patients, including hydration, dietary modifications, and mindfulness around portion size and satiety cues.
The importance of a multidisciplinary approach is reinforced, including psychological assessment (screening for eating disorders, depression, anxiety, and complications like sleep apnoea), dietitian involvement, and possible referral to exercise physiology and psychology services where also clinically indicated.
The Good GP Podcast is a proud member of the Talking HealthTech Podcast Network - the premier audio destination for cutting-edge insights and thought leadership in healthcare delivery, innovation, digital health, healthcare ICT, and commercialisation. Learn more at www.talkinghealthtech.com/podcast/network
If you have any questions or would like to contact The Good GP, send an email to [email protected]. Visit www.thegoodgp.com.au for previous episodes and more information.
More from The Good GP
In this episode of The Good GP, Dr Krystyna de Lange speaks with Dr Steph Daly, GP with a special interest in aged care and dementia, about the introduction of plasma biomarkers, specifically the p-Tau 217 blood test for Alzheimer’s disease. They explore what the p-Tau 217 test measures, its reliability, and its role in primary care.
In this episode of The Good GP, host Dr Krystyna De Lange speaks with Dr David Leitinger, a GP with a special interest in addiction medicine, about the practical use of naltrexone for managing alcohol use disorder (AUD).
In this episode of The Good GP, Dr Julia Rawlinson speaks with Dr Florence Martin, an epidemiologist specialising in pregnancy pharmacoepidemiology. Dr Martin discusses her recent study examining the relationship between first trimester antidepressant use and miscarriage risk, using UK primary care data from the CPRD GOLD database.
In this episode of the Good GP, Dr Julia Rawlinson speaks with Dr Julia Feutrill, consultant psychiatrist at King Edward Memorial Hospital and co-director of the Elizabeth Clinic. They discuss the complexities of antidepressant use during pregnancy, providing GPs with practical advice for navigating these conversations.
In this episode of the Good GP, Dr Julia Rawlinson speaks with Dr Paul Effler, Senior Medical Advisor at the WA Department of Health and expert in communicable diseases, about H5N1 avian influenza and pertussis.